Search
for
Sort by
Research 91–120 of 136
- Understanding, recognizing, and managing toxicities of targeted anticancer therapies
- Cutaneous manifestations and considerations in COVID ‐19 pandemic: A systematic review
- Immunosuppressive treatment for proliferative lupus nephritis
- Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer
- The L412F variant of Toll-like receptor 3 (TLR3) is associated with cutaneous candidiasis, increased susceptibility to cytomegalovirus, and autoimmunity
- Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease
- British Association of Dermatologists guidelines for the management of people with cutaneous lupus erythematosus 2021
- Clinical Features of Systemic Lupus Erythematosus Patients Complicated With Evans Syndrome
- Lithium: one drug, five complications
- Molecular Targeted Agents and Biologic Therapies for Non-small Cell Lung Cancer
- Cutaneous extramedullary haematopoiesis: Implications in human disease and treatment
- Immune therapies for alopecia areata: evidence and new perspectives
- Membranous nephropathy and lupus-like syndrome after hematopoietic cell transplantation: a case report
- Life threatening macrophage activation syndrome as the initial presentation of systemic lupus erythematosus: A case report and review of the literature
- Safety assessment of cyclin-dependent kinase 4/6 inhibitors and comparison of time to adverse events
- Delayed granulomatous eruption of the nose associated with ruxolitinib
- Challenges associated with the identification of germline variants on myeloid malignancy genomic profiling—a Singaporean experience
- Industry Updates from the Field of Stem Cell Research and Regenerative Medicine in December 2019
- Pharmacological Strategies for Mitigating Cytarabine-Induced Multi-Organ Toxicity: A Scoping Review on Mechanisms, Efficacy and Clinical Implications
- A Pilot Randomized Controlled Trial Comparing the Efficacy and Safety of Oral Tofacitinib Versus Methotrexate In Moderate-to-Severe Alopecia Areata
- Systemic Lupus Erythematosus: What Every Clinician Needs to Know
- Folliculotropic Mycosis Fungoides: Update on Diagnosis, Clinicopathological Stage, and Management
- Exosome-Based Therapies for Alopecia Areata: A Systematic Review of Clinical and Experimental Evidence
- A State-of-the-Art Overview on (Epi)Genomics and Personalized Skin Rejuvenating Strategies
- SLE classification criteria item relationships: implications on SLE as a disease entity
- Poster Presentations at the 28th Joint Meeting of the International Society of Dermatopathology, March 5–6, 2025, Orlando, Florida, USA
- BH06 (P075) A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
- P075 A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
- COLLAB: A Global Survey of Clinical and Laboratory Assessment in Alopecia Areata by Hair Specialists
- TRANSMEDCON 2022: E-Poster Abstracts